Skip to Main content Skip to Navigation
Master Thesis

Risque de diverticulite et de perforation digestive chez les patients atteints de polyarthrite rhumatoïde traités par tocilizumab en comparaison au rituximab et à l’abatacept : données extraites des registres nationaux REGATE, AIR-PR et ORA

Abstract : Objective: to investigate the risk of diverticulitis and gastrointestinal perforation (GIP) in patients with rheumatoid arthritis (RA) treated with tocilizumab (TCZ) compared to rituximab (RTX) and abatacept (ABA). Methods: we conducted a population-based study using three observational french registries evaluating the effectiveness and the safety of RTX, ABA, and TCZ in RA patients. Using a propensity score approach, we compared the risk of diverticulitis or GIP in these patients. Results: twenty-one vs 20 diverticulitis (corresponding incidence = 5.3 vs 2.3/1000 person-years) and 9 vs 10 GIP (2.3 vs 1.1/1000 person-years) occurred respectively in TCZ treated patients (n=1496) compared to RTX or ABA (n=3005). Based on inverse probability weighting, there were an increased risk of diverticulitis (OR 4.16 [95% CI 2.66-6.50]) and GIP (3.96 [2.18-7.20]) in TCZ treated patients compared to RTX and ABA. In a subgroup analysis, we observed an increased risk of GIP due to diverticulitis but not to any other etiology. Compared to RTX and ABA, diverticulitis and GIP among TCZ patients occurred earlier after the last perfusion (p=0.01), with atypical clinical presentation (slow transit in 30%, p=0.04) and lower acute phase reactants when the event occurred (C-reactive protein: 31.2±58.4 vs 88.2±89.6 mg/L, p=0.005). Conclusion: TCZ was associated with an increased risk of diverticulitis, GIP and GIP due to diverticulitis but not to other etiologies compared to RTX and ABA. Our study confirmed an increased risk of GIP in RA patients treated with TCZ that could be explained by an increased risk of diverticulitis with disconcerting clinical presentation.
Document type :
Master Thesis
Complete list of metadata

https://dumas.ccsd.cnrs.fr/dumas-03137822
Contributor : Scd Université de Montpellier <>
Submitted on : Wednesday, February 10, 2021 - 4:40:13 PM
Last modification on : Tuesday, June 22, 2021 - 11:36:02 AM
Long-term archiving on: : Tuesday, May 11, 2021 - 8:46:43 PM

File

C. Rempenault TM nouvelle vers...
Files produced by the author(s)

Licence


Distributed under a Creative Commons Attribution - NonCommercial - ShareAlike 4.0 International License

Identifiers

  • HAL Id : dumas-03137822, version 1

Citation

Claire Rempenault. Risque de diverticulite et de perforation digestive chez les patients atteints de polyarthrite rhumatoïde traités par tocilizumab en comparaison au rituximab et à l’abatacept : données extraites des registres nationaux REGATE, AIR-PR et ORA. Médecine humaine et pathologie. 2020. ⟨dumas-03137822⟩

Share

Metrics

Record views

23

Files downloads

343